Industry leaders meet at annual health care summit
Other changes sought to reduce regulatory burden
Laparoscopic morcellators spread cancer cells
Landmark bill heads for Senate vote
Seema Verma’s consulting firm helped shape Medicaid expansion in Indiana
Martin Shkreli takes a slap in the face
Attacks on critical infrastructure seen as ‘acts of war’
Ciprofloxacin formulation studied in lung infections

P&T November 2016
Table of Contents


The Centers for Medicare and Medicaid Services’ addition of drug utilization categories to the risk-assessment process aims to make scores more sensitive and accurate, which may help stem the exodus of companies from the marketplace.
After incorporating system formulary-related information and related resources into a single commercial formulary management tool, one health system increased pharmacist end-user satisfaction and overall use of formulary-related information.
Rapid-acting bronchodilators, systemic corticosteroids, and antibiotics are among the keys to managing exacerbations of chronic obstructive pulmonary disease. Preventing exacerbations should also be a component of therapy for the disease.
To address the need for updated pregnancy risk categories, the Food and Drug Administration published a final rule in 2014. The authors review the changes the rule makes, its implementation schedule, and its potential clinical impact.
Researchers surveyed pharmacists’ preparedness for the state’s medical cannabis program and found that more training and education on the regulatory and clinical aspects of cannabis were needed in preparation for their work with patients.


Medication Errors
Using a saline flush “site unseen” could lead to a wrong-route error
Prescription: Washington
Can the FDA do more to encourage orphan drug development?
Approvals, new indications, regulatory activities, and more
Calcifediol (Rayaldee) for secondary hyperparathyroidism in adults with chronic kidney disease; dasabuvir/ombitasvir/paritaprevir/ritonavir (Viekira XR) for hepatitis C virus infection; and lixisenatide (Adlyxin) for type-2 diabetes
Drug Forecast
Perampanel (Fycompa): a review of clinical efficacy and safety in epilepsy


The Role of T-VEC and Other Intralesional Agents

Robert H. I. Andtbacka, MD, of the Huntsman Cancer Institute in Utah, discusses the place in therapy of talimogene laherparepvec (T-VEC) and other intralesional oncolytic agents for melanoma patients, both as monotherapy and in combination with treatments including checkpoint inhibitors.

American Society of Clinical Oncology, June 2016